Company intelligence / Profile preview
TargImmune Therapeutics
Basel, Switzerlandtargimmune.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Other
01
Overview
TargImmune’s lead candidate TAR001, targeting EGFR-expressing solid tumors, has demonstrated proof-of-concept in vivo and successfully completed GLP/toxicity studies. The company is preparing for clinical trial application filings with the aim of entering first-in-human trials. The Ta:RNA™ platform enables selective destruction of cancer cells while stimulating an immune response.
- Therapeutic areas
- Oncology
- Modalities
- Synthetic nanoparticles for nucleic acid deliveryDouble-stranded RNA (dsRNA) therapeuticsTargeted Apoptotic Immunomodulators (TAIMs)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on TargImmune Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TargImmune Therapeutics.